Therefore, mutant EGFR-driven NSCLC has a unique immunosuppressive microenvironment, and EGFR activation promotes the expression of VEGF, which is expected to result in tumor angiogenesis. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.